| Literature DB >> 35540302 |
Ying Huang1,2, Yi-Xin Huang2, Jing Sun1, Chao-Guo Yan1.
Abstract
The three-component reaction of 1,2,3,4-tetrahydroisoquinoline, isatins and 3-phenacylideneoxindoles in refluxing ethanol afforded dispiro[indoline-3,1'-pyrrolo[2,1-a]isoquinoline-3',3'-indolines] (4a-4x) in good yields via 1,3-dipolar cycloaddition of in situ generated azomethine ylide with the exocyclic double bond of 3-phenacylideneoxindoles. 1H NMR spectra and single crystal structures indicated the reaction has high regioselectivity and diastereoselectivity. Furthermore, their biological activities have been preliminarily demonstrated by in vitro evaluation against mouse breast cancer cells 4T1 and human liver cancer cells HepG2 by MTT assay. The results demonstrated that some of the compounds showed cytotoxicities to cell lines of 4T1 and HepG2, and indicated that novel spirooxindoles may become potential lead compounds for further biological screenings of their medicinal applications. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35540302 PMCID: PMC9081698 DOI: 10.1039/c8ra04375b
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Representative spiropyrrolidinyl oxindole alkaloids.
Scheme 1Three-component reaction for dispirooxindole 4a.
Three-component reaction for synthesis of spirooxindoles 4a–xa
|
| |||||||
|---|---|---|---|---|---|---|---|
| Entry | Compd | R1 | R2 | R3 | R4 | R5 | Yield |
| 1 | 4a | CH3 | H | CH3 | H | CH3 | 70 |
| 2 | 4b | CH3 | H | Cl | H | OCH3 | 76 |
| 3 | 4c | Cl | H | CH3 | H | CH3 | 81 |
| 4 | 4d | CH3 | H | H | H | H | 90 |
| 5 | 4e | CH3 | H | CH3 | H | Cl | 80 |
| 6 | 4f | CH3 | H | Cl | H | CH3 | 50 |
| 7 | 4g | Cl | H | CH3 | H | Cl | 82 |
| 8 | 4h | Cl | H | Cl | H | OCH3 | 67 |
| 9 | 4i | Cl | H | F | H | CH3 | 57 |
| 10 | 4j | CH3 | H | Cl | CH2Ph | Cl | 57 |
| 11 | 4k | CH3 | H | H | CH2Ph | H | 58 |
| 12 | 4l | CH3 | H | CH3 | CH2Ph | CH3 | 62 |
| 13 | 4m | CH3 | H | CH3 | CH2Ph | Cl | 66 |
| 14 | 4n | CH3 | H | CH3 | C4H9 | CH3 | 90 |
| 15 | 4o | Cl | H | Cl | C4H9 | CH3 | 72 |
| 16 | 4p | H | CH3 | CH3 | H | CH3 | 85 |
| 17 | 4q | H | CH3 | Cl | H | CH3 | 63 |
| 18 | 4r | H | CH3 | CH3 | CH2Ph | Cl | 58 |
| 19 | 4s | CH3 | CH2Ph | CH3 | H | CH3 | 79 |
| 20 | 4t | CH3 | CH2Ph | Cl | H | OCH3 | 80 |
| 21 | 4u | CH3 | CH2Ph | Cl | H | CH3 | 62 |
| 22 | 4v | Cl | CH2Ph | Cl | H | CH3 | 76 |
| 23 | 4w | CH3 | CH2Ph | CH3 | CH2Ph | Cl | 60 |
| 24 | 4x | Cl | C4H9 | CH3 | H | CH3 | 50 |
Reaction conditions: isatin (0.30 mmol), tetrahydroisoquinoline (0.30 mmol), 3-phenacylideneoxindole (0.25 mmol); reflux, 7 h.
Isolated yields.
Ratio of 4t : 4′t = 90 : 10.
Ratio of 4u : 4′u = 75 : 25.
Fig. 2Single crystal structure of compound 4a.
Fig. 3Single crystal structure of compound 4u.
Fig. 4Single crystal structure of compound 4v.
Preliminary evaluation on the anticancer activities of synthesized compounds 4a–x on 4T1 and HepG2 cancer cell lines (200 μg mL−1)a
| Compound | 4T1 cell death | HepG2 cell death | ||||||
|---|---|---|---|---|---|---|---|---|
| 24 h | 48 h | 24 h | 48 h | |||||
| % | Mean ± S.D. | % | Mean ± S.D. | % | Mean ± S.D. | % | Mean ± S.D. | |
| 4a | 2.31 | 0.915 ± 0.011 | 25.80 | 0.870 ± 0.015 | 2.84 | 0.868 ± 0.024 | 32.86 | 0.506 ± 0.004 |
| 4b | 2.23 | 0.916 ± 0.016 | 15.05 | 0.984 ± 0.014 | 3.99 | 0.858 ± 0.023 | 19.34 | 0.591 ± 0.110 |
| 4c | 6.99 | 0.871 ± 0.015 | 20.36 | 0.928 ± 0.010 | 5.67 | 0.843 ± 0.016 | 19.71 | 0.589 ± 0.060 |
| 4d | 6.35 | 0.877 ± 0.040 | 20.82 | 0.923 ± 0.014 | 7.16 | 0.830 ± 0.016 |
| 0.145 ± 0.046 |
| 4e | 7.88 | 0.863 ± 0.022 | 20.64 | 0.925 ± 0.060 | 2.97 | 0.867 ± 0.014 | 13.27 | 0.629 ± 0.058 |
| 4f | 6.45 | 0.876 ± 0.012 | 19.43 | 0.937 ± 0.098 | 4.59 | 0.853 ± 0.013 | 14.22 | 0.623 ± 0.045 |
| 4g | / | 0.940 ± 0.061 | 27.64 | 0.851 ± 0.034 | 3.71 | 0.861 ± 0.012 | 23.16 | 0.567 ± 0.056 |
| 4h | 5.23 | 0.887 ± 0.045 | 23.25 | 0.896 ± 0.137 | 6.12 | 0.839 ± 0.013 |
| 0.098 ± 0.006 |
| 4i | 10.38 | 0.839 ± 0.025 | 33.31 | 0.791 ± 0.068 | 5.34 | 0.846 ± 0.028 |
| 0.088 ± 0.004 |
| 4j | 3.42 | 0.904 ± 0.020 | 17.87 | 0.954 ± 0.051 | 5.02 | 0.849 ± 0.019 | 25.25 | 0.554 ± 0.066 |
| 4k | 3.43 | 1.329 ± 0.112 | 10.88 | 1.237 ± 0.033 | / | 1.193 ± 0.024 | 2.36 | 1.211 ± 0.106 |
| 4l | / | 1.423 ± 0.013 | 10.54 | 1.241 ± 0.017 | / | 1.208 ± 0.012 | / | 1.563 ± 0.177 |
| 4m | 8.16 | 1.268 ± 0.032 | 20.71 | 1.099 ± 0.084 | / | 1.184 ± 0.003 | 4.22 | 1.188 ± 0.012 |
| 4n | 4.28 | 1.318 ± 0.018 | 15.68 | 1.169 ± 0.057 | 0.66 | 1.170 ± 0.019 | 11.82 | 1.094 ± 0.026 |
| 4o | 0.23 | 1.370 ± 0.021 | 12.69 | 1.211 ± 0.020 | / | 1.208 ± 0.030 | / | 1.441 ± 0.229 |
| 4p | / | 1.377 ± 0.011 | 22.86 | 1.070 ± 0.040 | / | 1.180 ± 0.028 | / | 1.393 ± 0.424 |
| 4q | / | 1.514 ± 0.009 | 4.65 | 1.322 ± 0.018 | 23.9 | 0.897 ± 0.022 | 9.88 | 1.118 ± 0.137 |
| 4r | / | 1.402 ± 0.027 | 5.11 | 1.316 ± 0.021 | / | 1.217 ± 0.018 | / | 1.285 ± 0.113 |
| 4s | / | 1.376 ± 0.016 | 8.20 | 1.273 ± 0.007 | / | 1.292 ± 0.025 | 7.23 | 1.151 ± 0.048 |
| 4t | / | 1.481 ± 0.016 | / | 1.465 ± 0.028 | / | 1.385 ± 0.020 | 10.09 | 1.115 ± 0.069 |
| 4u | 2.75 | 1.108 ± 0.039 | / | 1.131 ± 0.001 | 2.75 | 1.117 ± 0.154 | 1.053 ± 0.019 | |
| 4v | / | 1.125 ± 0.065 | / | 1.211 ± 0.021 | / | 1.172 ± 0.018 | / | 1.036 ± 0.010 |
| 4w | 2.40 | 1.187 ± 0.060 | 5.249 | 1.197 ± 0.005 | 2.40 | 1.121 ± 0.038 | 5.25 | 0.947 ± 0.026 |
| 4x | / | 1.185 ± 0.033 | / | 1.201 ± 0.002 | / | 1.194 ± 0.042 | / | 1.314 ± 0.110 |
/: no activity.
Preliminary evaluation on the anticancer activities of 4d, 4h and 4i on HepG2 cancer cell lines
| Compound | 200 μg mL−1 | 100 μg mL−1 | 50 μg mL−1 | |||
|---|---|---|---|---|---|---|
| Cell death | Cell death | Cell death | ||||
| % | Mean ± S.D. | % | Mean ± S.D. | % | Mean ± S.D. | |
| 4d | 67.40 | 0.325 ± 0.018 | 30.93 | 0.691 ± 0.062 | 16.12 | 0.838 ± 0.040 |
| 4h | 59.74 | 0.402 ± 0.014 | 30.64 | 0.693 ± 0.028 | 20.57 | 0.794 ± 0.028 |
| 4i | 79.30 | 0.209 ± 0.040 | 70.40 | 0.474 ± 0.056 | 44.08 | 0.559 ± 0.003 |
Fig. 5The morphological features of survival status were monitored by fluorescence microscopy after staining with DAPI.
Fig. 6Effect of compound 4d, 4h and 4i on 3T3 cell viabilities (200 μg mL−1).